CY1725A - Combination dosage form for pre-menopausal women - Google Patents

Combination dosage form for pre-menopausal women

Info

Publication number
CY1725A
CY1725A CY172594A CY172594A CY1725A CY 1725 A CY1725 A CY 1725A CY 172594 A CY172594 A CY 172594A CY 172594 A CY172594 A CY 172594A CY 1725 A CY1725 A CY 1725A
Authority
CY
Cyprus
Prior art keywords
dosage form
days
combination
combination dosage
estradiol
Prior art date
Application number
CY172594A
Other languages
English (en)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1725(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of CY1725A publication Critical patent/CY1725A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CY172594A 1986-07-15 1994-05-06 Combination dosage form for pre-menopausal women CY1725A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88597186A 1986-07-15 1986-07-15

Publications (1)

Publication Number Publication Date
CY1725A true CY1725A (en) 1994-05-06

Family

ID=25388101

Family Applications (1)

Application Number Title Priority Date Filing Date
CY172594A CY1725A (en) 1986-07-15 1994-05-06 Combination dosage form for pre-menopausal women

Country Status (20)

Country Link
EP (1) EP0253607B2 (es)
JP (1) JP2645510B2 (es)
KR (1) KR960001371B1 (es)
AT (1) ATE75401T1 (es)
AU (1) AU597084B2 (es)
CY (1) CY1725A (es)
DE (1) DE3778599D1 (es)
DK (2) DK174724B1 (es)
ES (1) ES2033850T5 (es)
GB (1) GB2192542B (es)
GR (1) GR3004472T3 (es)
HK (1) HK67393A (es)
IE (1) IE61236B1 (es)
LU (1) LU90634I2 (es)
NL (1) NL300025I2 (es)
PH (1) PH25944A (es)
PT (1) PT85305B (es)
SG (1) SG55093G (es)
WO (1) WO1988000469A1 (es)
ZA (1) ZA875010B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
CH674618A5 (es) * 1987-04-02 1990-06-29 Ciba Geigy Ag
DE3864210D1 (de) * 1987-07-06 1991-09-19 Akzo Nv Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden.
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
FI101601B (fi) * 1987-09-24 1998-07-31 Jencap Res Ltd Ehkäisyvalmiste sekä estrogeenin ja progestiinin käyttö ehkäisyvalmist een valmistusmenetelmässä
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
US5043331A (en) * 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
CN1186024C (zh) * 1996-07-26 2005-01-26 惠氏公司 单阶段避孕方法和含有黄体酮和雌激素组合物的避孕药盒
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
WO1999009993A1 (en) * 1997-08-27 1999-03-04 Ortho Pharmaceutical Corporation Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
EP1453521B1 (en) 2001-12-05 2013-09-04 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
EP1624848A4 (en) 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
NZ585546A (en) 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
JP2007511533A (ja) 2003-11-14 2007-05-10 ワーナー・チルコット・カンパニー・インコーポレーテッド 段階的エストロゲン避妊薬
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2392332A1 (en) 2004-10-07 2011-12-07 Teva Women's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
WO2007076144A2 (en) 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
TW200840595A (en) * 2006-12-12 2008-10-16 Organon Nv Oral contraceptive spray
MX2009006823A (es) * 2006-12-20 2009-07-03 Duramed Pharmaceuticals Inc Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas.
US20090170823A1 (en) 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
WO2009112232A2 (en) * 2008-03-10 2009-09-17 Vladimir Hanes New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
ES2734510T3 (es) 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2343979B1 (en) 2008-10-08 2020-04-08 Agile Therapeutics, Inc. Transdermal delivery
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
JP2018515552A (ja) * 2015-05-18 2018-06-14 アジル・セラピューティクス・インコーポレイテッドＡｇｉｌｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 避妊用組成物ならびに有効性改善および副作用調節方法
EP3272333A1 (en) 2016-07-22 2018-01-24 Chemo Research, S.L. Vaginal composition comprising a combination of estrogen and vitamin d

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3669502A (en) † 1971-01-05 1972-06-13 Simpson Timber Co Pneumatic spreader stoker
US3836651A (en) * 1972-02-22 1974-09-17 Biolog Concepts Inc Novel oral contraceptive combination
DE2310963A1 (de) † 1972-04-14 1974-09-05 Schering Ag Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
DE2365103C3 (de) † 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
ZA87332B (en) † 1986-02-27 1987-08-26 Warner Lambert Co Compositions containing fixed combinations

Also Published As

Publication number Publication date
JPH01500431A (ja) 1989-02-16
WO1988000469A1 (en) 1988-01-28
GR3004472T3 (es) 1993-03-31
AU597084B2 (en) 1990-05-24
KR880701553A (ko) 1988-11-03
DK351887D0 (da) 1987-07-08
EP0253607B2 (en) 2001-05-23
ES2033850T3 (es) 1993-04-01
IE871833L (en) 1988-01-15
EP0253607B1 (en) 1992-04-29
DE3778599D1 (de) 1992-06-04
JP2645510B2 (ja) 1997-08-25
NL300025I1 (nl) 2001-01-02
ES2033850T5 (es) 2001-07-01
ZA875010B (en) 1989-02-22
DK351887A (da) 1988-01-16
NL300025I2 (nl) 2004-08-02
DK174724B1 (da) 2003-10-06
EP0253607A1 (en) 1988-01-20
KR960001371B1 (ko) 1996-01-26
IE61236B1 (en) 1994-10-19
GB8716431D0 (en) 1987-08-19
DK365887D0 (da) 1987-07-14
ATE75401T1 (de) 1992-05-15
PH25944A (en) 1991-12-19
GB2192542A (en) 1988-01-20
LU90634I2 (fr) 2000-12-15
PT85305B (pt) 1990-03-30
SG55093G (en) 1993-07-09
PT85305A (en) 1987-08-01
AU7537987A (en) 1988-01-21
GB2192542B (en) 1990-05-02
HK67393A (en) 1993-07-23

Similar Documents

Publication Publication Date Title
GB2192542B (en) Combination dosage form for pre-menopausal women
EP0717626B1 (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
EP0911029B1 (en) Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
CA2179728A1 (en) Composition for a contraceptive comprising an estrogen and a gestagen
RU96115196A (ru) Состав для контрацепции
JP2000502108A (ja) ゲストゲンとエストロゲン併用によるほ乳動物の避妊法とキット
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
LU90341I2 (fr) 75 Ug de désogestrel en l'absence éthinyl oestradiol (cerazette)
NZ333862A (en) Triphasic oral contraceptive method and kit comprising a combination of progestin and estrogen
JP2942560B2 (ja) エストロゲン欠乏症治療用組成物
CA2311937A1 (en) Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
Olsson Vaginal rings for contraception: endocrine parameters